I do not think that CEO Lewis will suggest anything about this except to clarify Premacure and the licensing rights to treat premies has been bought by Shire. Other than the royalty obligation back to INSM by Shire/Premacure, there is not much. The back door is that once Iplex is again being made, there are other outlicensing opportunities for INSM. They will also be on a royalty basis. INSM will not in the foreseeable future get back into any clinical situations with Iplex. Lots of reasons why. But the clinical endpoints would all have to be re-evaluated and restructured into trials. INSM will have its hands full getting Arikace to market. Besides, GA and Glover, the two former INSM employees who were knowledgeable about FOB, proteonomics, recombinant protein production, etc. are all gone from INSM.
Rehd, let's for the sake of argument say that you are right that for the foreseeable future this opportunity with Shire is on a royalty basis and other outlicensing basis. Doesn't this bode well with regards to the financial situation for Insmed as they ramp up for bringing Arikace to market?
Anyone thinking this deal was contingent on Ipsen waiving rights to Premiplex, which I believe Lewis hinted was coming? If so, maybe now INSM can openly discuss business possibilities surrounding the compound.